Cortisol secretion and abnormalities of glucose metabolism in nondiabetic patients with hypertension.
暂无分享,去创建一个
C. Catena | L. Sechi | A. Da Porto | G. Brosolo | N. Bertin | A. Vacca | Luca Bulfone
[1] C. Catena,et al. Association of arterial stiffness with a prothrombotic state in uncomplicated nondiabetic hypertensive patients , 2023, Frontiers in Cardiovascular Medicine.
[2] Eric L. Johnson,et al. 3. Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Care in Diabetes-2023. , 2022, Diabetes care.
[3] Eric L. Johnson,et al. 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2023. , 2022, Diabetes care.
[4] C. Catena,et al. Association of non-alcoholic fatty liver disease with left ventricular changes in treatment-naive patients with uncomplicated hypertension , 2022, Frontiers in Cardiovascular Medicine.
[5] A. Tabarin,et al. Diagnosis and management of hypertension in patients with Cushing's syndrome: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension , 2022, Journal of hypertension.
[6] C. Catena,et al. Differences in Regulation of Cortisol Secretion Contribute to Left Ventricular Abnormalities in Patients With Essential Hypertension , 2022, Hypertension.
[7] C. Catena,et al. Vitamin D Deficiency Is Associated with Glycometabolic Changes in Nondiabetic Patients with Arterial Hypertension , 2022, Nutrients.
[8] C. Catena,et al. Plasma Lipoprotein(a) Levels as Determinants of Arterial Stiffening in Hypertension , 2021, Biomedicines.
[9] J. Sowers,et al. Hypertension in Diabetes: An Update of Basic Mechanisms and Clinical Disease , 2021, Hypertension.
[10] P. Chanson,et al. Consensus on diagnosis and management of Cushing's disease: a guideline update. , 2021, The lancet. Diabetes & endocrinology.
[11] M. Alderman. Prediabetes: an unexplored cardiovascular disease risk factor. , 2021, Journal of hypertension.
[12] Yen-Hung Lin,et al. Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension. , 2020, Journal of hypertension.
[13] M. Omura,et al. Changes in glucose metabolism based on 75-g oral glucose tolerance tests before and after surgery for adrenal Cushing's syndrome. , 2019, Endocrine journal.
[14] W. Rathmann,et al. Impaired Glucose Metabolism in Primary Aldosteronism Is Associated With Cortisol Cosecretion. , 2019, The Journal of clinical endocrinology and metabolism.
[15] Thomas Kahan,et al. [2018 ESC/ESH Guidelines for the management of arterial hypertension]. , 2019, Kardiologia polska.
[16] M. Lanaspa,et al. Fasting blood glucose is predictive of hypertension in a general Japanese population , 2018, Journal of hypertension.
[17] F. Ceccato,et al. Diabetes Mellitus Secondary to Cushing’s Disease , 2018, Front. Endocrinol..
[18] O. Dekkers,et al. Mortality in patients with Cushing's disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study. , 2016, The lancet. Diabetes & endocrinology.
[19] M. Kivimäki,et al. Diurnal Cortisol Patterns, Future Diabetes, and Impaired Glucose Metabolism in the Whitehall II Cohort Study. , 2016, The Journal of clinical endocrinology and metabolism.
[20] Martin Reincke,et al. Subclinical hypercortisolism: a state, a syndrome, or a disease? , 2015, European journal of endocrinology.
[21] C. Catena,et al. Carotid artery stiffness is related to hyperinsulinemia and insulin-resistance in middle-aged, non-diabetic hypertensive patients. , 2015, Nutrition, metabolism, and cardiovascular diseases : NMCD.
[22] A. Steptoe,et al. Association of diurnal patterns in salivary cortisol with type 2 diabetes in the Whitehall II study. , 2014, The Journal of clinical endocrinology and metabolism.
[23] V. Guarnotta,et al. Is diabetes in Cushing's syndrome only a consequence of hypercortisolism? , 2014, European journal of endocrinology.
[24] T. Kuo,et al. Metabolic functions of glucocorticoid receptor in skeletal muscle , 2013, Molecular and Cellular Endocrinology.
[25] L. Sechi,et al. Plasma glucose levels and left ventricular diastolic function in nondiabetic hypertensive patients. , 2013, American journal of hypertension.
[26] W. Cushman,et al. Diabetes and hypertension: the bad companions , 2012, The Lancet.
[27] R. DeFronzo,et al. Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. , 2011, The American journal of cardiology.
[28] P. Jones,et al. Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. , 2011, The Journal of clinical endocrinology and metabolism.
[29] D. Levy,et al. Blood Pressure and the Risk of Developing Diabetes in African Americans and Whites , 2011, Diabetes Care.
[30] P. Nilsson,et al. Metabolic characteristics of prehypertension: role of classification criteria and gender , 2009, Journal of hypertension.
[31] J. Holst,et al. Pathophysiology and aetiology of impaired fasting glycaemia and impaired glucose tolerance: does it matter for prevention and treatment of type 2 diabetes? , 2009, Diabetologia.
[32] D. Ouwens,et al. Novel insights into glucocorticoid‐mediated diabetogenic effects: towards expansion of therapeutic options? , 2009, European journal of clinical investigation.
[33] P. Stewart,et al. Impaired Glucose Tolerance and Insulin Resistance Are Associated With Increased Adipose 11β-Hydroxysteroid Dehydrogenase Type 1 Expression and Elevated Hepatic 5α-Reductase Activity , 2008, Diabetes.
[34] A. Stuck,et al. Age-dependent Decrease in 11 β-Hydroxysteroid Dehydrogenase Type 2 ( 11 β-HSD 2 ) Activity in Hypertensive Patients , 2008 .
[35] B. Walker,et al. Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome. , 2008, The Journal of endocrinology.
[36] R. Krauss,et al. Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement , 2005, Current opinion in cardiology.
[37] H. Cohen,et al. Glucocorticoids Regulate Transcription of the Gene for Phosphoenolpyruvate Carboxykinase in the Liver via an Extended Glucocorticoid Regulatory Unit* , 2005, Journal of Biological Chemistry.
[38] G. Reboldi,et al. Adverse Prognostic Significance of New Diabetes in Treated Hypertensive Subjects , 2004, Hypertension.
[39] L. Sechi,et al. Serum lipoprotein(a) concentrations and alcohol consumption in hypertension: possible relevance for cardiovascular damage , 2003, Journal of hypertension.
[40] B. Walker,et al. Abnormal cortisol metabolism and tissue sensitivity to cortisol in patients with glucose intolerance. , 2002, The Journal of clinical endocrinology and metabolism.
[41] C. Catena,et al. Abnormalities of glucose metabolism in patients with early renal failure. , 2002, Diabetes.
[42] B. Walker,et al. Elevated plasma cortisol in glucose-intolerant men: differences in responses to glucose and habituation to venepuncture. , 2001, The Journal of clinical endocrinology and metabolism.
[43] B. Walker,et al. Glucocorticoids and insulin resistance: old hormones, new targets. , 1999, Clinical science.
[44] P. Gilon,et al. Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets. , 1997, The Journal of clinical investigation.
[45] H. Parving,et al. Prevalence of Arterial Hypertension in Diabetic Patients Before and After the JNC-V , 1994, Diabetes Care.
[46] S. Agewall. Should we do an oral glucose tolerance test in hypertensive men with normal fasting blood-glucose? , 2001, Journal of Human Hypertension.